Zymeworks Inc. (ZYME)
| Market Cap | 1.87B +137.0% |
| Revenue (ttm) | 81.26M -13.0% |
| Net Income | -102.66M |
| EPS | -1.36 |
| Shares Out | 73.02M |
| PE Ratio | n/a |
| Forward PE | 15.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 226,823 |
| Open | 25.20 |
| Previous Close | 25.11 |
| Day's Range | 24.94 - 25.68 |
| 52-Week Range | 11.02 - 29.75 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 40.15 (+56.78%) |
| Earnings Date | May 7, 2026 |
About ZYME
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead pr... [Read more]
Financial Performance
In 2025, Zymeworks's revenue was $105.97 million, an increase of 38.87% compared to the previous year's $76.30 million. Losses were -$81.13 million, -33.88% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ZYME stock is "Strong Buy." The 12-month stock price target is $40.15, which is an increase of 56.78% from the latest price.
News
Zymeworks authorizes share repurchase program of up to $125M
Zymeworks (ZYME) announced that its board of directors has authorized a share repurchase program under which the company may repurchase up to $125M of its outstanding common stock. “The authorization…
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipel...
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipel...
Zymeworks Q1 Earnings Call Highlights
Zymeworks NASDAQ: ZYME reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across ...
Zymeworks reports Q1 EPS (59c), consensus (10c)
Reports Q1 revenue $2.4M, consensus $35.58M. The revenue decrease was driven mainly by the achievement of non-recurring clinical milestone payments in 2025, as well as continued declines in developmen...
Zymeworks Earnings Call Transcript: Q1 2026
Q1 2026 saw regulatory progress for zanidatamab, strong cash reserves, and pipeline advances in ADCs, with revenue down year-over-year due to non-recurring milestones. Share repurchases and anticipated milestone payments support long-term funding and value creation.
Zymeworks Earnings release: Q1 2026
Zymeworks released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Zymeworks Slides: Q1 2026
Zymeworks has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Zymeworks Quarterly report: Q1 2026
Zymeworks has published its Q1 2026 quarterly earnings report on May 7, 2026.
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gas...
Zymeworks reports results from dose-escalation part of Phase 1 study for ZW191
Zymeworks (ZYME) announced results from the dose-escalation part of the Phase 1 study for ZW191, a folate receptor alpha, or FRalpha,-targeting antibody-drug conjugate, or ADC, at the 2026 American As...
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip...
Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
Biotech innovation is gaining renewed investor recognition, driving sector growth and M&A activity. A strong financial position enables sustained R&D, strategic acquisitions, and shareholder returns, with a robust pipeline and key catalysts ahead, including FDA reviews and pivotal clinical data.
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Six poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable to...
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip...
Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is evolving into a diversified asset aggregator, combining robust internal R&D with strategic royalty and asset acquisitions. Strong financials, highlighted by a $250 million Royalty Pharma deal and a $125 million share repurchase program, support a long runway and ongoing pipeline expansion in oncology and immunology.
Zymeworks appoints new Head of R&D and Chief Business Officer
Zymeworks (ZYME) announced the full-time appointments of Adam Schayowitz and Scott Platshon as of April 9, from their previously interim roles. Schayowitz has been appointed as EVP and Head of…
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer
Zymeworks appoints Kristin Stafford as CFO
Zymeworks (ZYME) announced the appointment of Kristin Stafford as CFO, effective April 1. Stafford recently served as Senior Vice President, Chief Accounting Officer for Royalty Pharma plc, since Dece...
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi...
Zymeworks receives FDA Fast Track Designation for ZW191
Zymeworks (ZYME) announced that the U.S.FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate targeting folate receptor-alpha, for the treatment of patients with advanced or meta...
Zymeworks announces Fast Track designation for ZW191 by FDA
Zymeworks (ZYME) announced that the FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-alpha, for the treatment of patients with advanced or me...
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pi...
Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting
Zymeworks (ZYME) announced that the company’s partner, Jazz Pharmaceuticals (JAZZ), will present four abstracts featuring data from clinical trials evaluating Ziihera at the American Association for C...
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip...